drugset / Trial / NCT03177798

Mitochondria and Chronic Kidney Disease

NCT03177798

Phase 2 Completed 11 enrolled Vanderbilt University Medical Center
RandomizedCrossoverQuadruple-blindPrevention

Summary

The overarching goal of this study is to determine the role of chronic kidney disease and the activation of the kallikrein-kinin system during hemodialysis on the development of mitochondrial dysfunction; the investigators will measure mitochondrial function using the gold standard method, 31-phosphorus magnetic resonance spectroscopy. The investigators will test the hypothesis that endogenous bradykinin promotes mitochondrial dysfunction in patients undergoing hemodialysis. The investigators will first perform a randomized, placebo-controlled, double-blind, cross-over study measuring the effect of Icatibant (HOE-140), a bradykinin B2 receptor blocker, on mitochondrial function.

Timeline

Start
2017-08-01
Primary completion
2018-06-30
Completion
2018-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Icatibant Peptide 50 ug/kg Intravenous